title: Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools.
abstract: The recent identification of key molecular protagonists involved in osteoclast biology has led to the development of new therapeutic approaches of osteolytic diseases using biological molecules which could compete with bisphosphonate therapy.
authors.affiliation: Pathophysiology of Bone Resorption Laboratory and Therapy of Primitive Bone Tumors, EA3822, INSERM ERI 7, Medicine Faculty, 1 rue Gaston Veil, 44035 Nantes cedex 1, France. dominique.heymann@univ-nantes.fr
authors.forename: Dominique
authors.initials: D
authors.lastname: Heymann
authors.forename: Yannick
authors.initials: Y
authors.lastname: Fortun
authors.forename: Francoise
authors.initials: F
authors.lastname: Rédini
authors.forename: Marc
authors.initials: M
authors.lastname: Padrines
mesh_terms: D000818:Animals; D004164:Diphosphonates / Q000627:therapeutic use; D015195:Drug Design; D006023:Glycoproteins / Q000627:therapeutic use; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors; D018716:Molecular Mimicry; D010014:Osteolysis / Q000188:drug therapy*; D053244:Osteoprotegerin; D010455:Peptides / Q000737:chemistry; D018160:Receptors, Cytoplasmic and Nuclear / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D004164:Diphosphonates; D006023:Glycoproteins; D039302:Integrin alphaVbeta3; D053244:Osteoprotegerin; D010455:Peptides; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; D011994:Recombinant Proteins; C506030:TNFRSF11B protein, human